human health

TESTs
 

 

The Pandemic

Coronavirus Disease 2019 (COVID-19), an acute respiratory illness caused by infection with the SARS-CoV-2, was initially reported to WHO in Wuhan, China, on December 31, 2019. The SARS-CoV-2 can be transmitted from person to person through the nose, eyes, or mouth. Furthermore, symptoms of SARS-CoV-2 infection vary. It can be asymptomatic or cause mild illnesses, including a runny nose, sore throat, cough, and fever. However, in severe cases, it can lead to pneumonia, breathing difficulties, or death. To date, millions of people around the world have died from COVID-19.Coronavirus Disease 2019 (COVID-19), an acute respiratory illness caused by infection with the SARS-CoV-2, was initially reported to WHO in Wuhan, China, on December 31, 2019. The SARS-CoV-2 can be transmitted from person to person through the nose, eyes, or mouth. Furthermore, symptoms of SARS-CoV-2 infection vary. It can cause mild illnesses, including a runny nose, sore throat, cough, and fever. However, in severe cases, it can lead to pneumonia, breathing difficulties, or death.

 

 

The Need

As the world continues to combat COVID-19, SARS-CoV-2 testing keeps playing a crucial role in stopping the spread of the virus and future variants. Particularly, a rapid and accurate diagnostic test for SARS-CoV-2 detection at the Point-of-Care becomes essential and generally adopted to help healthcare professionals to make decisions on the spot.

 

 

The Solution

VitaPCR™ SARS-CoV-2 Gen 2 Assay based on the proprietary RT-PCR technology provides significantly faster testing results than any other laboratory-based methods with higher accuracy than conventional rapid testing. With less than a minute of hands-on time, the test allows the detection of SARS-CoV-2 in 20 minutes from sample to results. On top of that, the comprehensive results information, including Ct values and fluorescence curves, can help healthcare providers make precise decisions and offer proper treatments in a timely manner.

 

 

icon Usability new

Usability

Minimal Training Required

 

No additional equipment needed

 

Room Temperature Storage

 

 

icon Performance new

Performance

High Accuracy

 

Short Turnaround Time

 

Intuitive result interpretation with
Ct value & Fluorescence Curve

 

 

 

General Diagnostic Procedure

 
GENERAL DIAGNOSTIC PROCEDURE 01024x GENERAL DIAGNOSTIC PROCEDURE 0304FDA4x copy

 

Intuitive Result Interpretation

 

ResultCT SC2 100

 



 

 

 SC2 Gen2 fix border

 

 

VitaPCR™ SARS-CoV-2 Gen 2 Assay Specifications
Catalog No. PCRAE0120
Technology Real-Time RT-PCR
Targets N1, N2 – Nucleocapsid Gene
Quantity 20 tests/box
Sample Types Nasopharyngeal or Oropharyngeal Swabs
Hands-on Time < 1 min
Turnaround Time 20 mins
Kit Storage 5 - 25 °C / 41 - 77 °F

 

Reference

  1. Trigt RV, Neat J, Brouwer JL, Hays A, Westerhof H. Deploying a rapid point of care polymerase chain reaction test for SARS-CoV-2 in a clinical research unit to ensure healthy volunteer safety. Bioanalysis. 2021;10.4155/bio-2021-0079.

  2. Musumeci A, Vinci M, L'Episcopo F, et al. Implementation of Sample Pooling Procedure Using a Rapid SARS-CoV-2 Diagnostic Real-Time PCR Test Performed Prior to Hospital Admission of People with Intellectual Disabilities. Int J Environ Res Public Health. 2021;18(17):9317.

  3. Fournier PE, Edouard S, Wurtz N, et al. Contagion Management at the Méditerranée Infection University Hospital InstituteJ Clin Med. 2021;10(12):2627.

  4. Fitoussi, F., Dupont, R., Tonen-Wolyec, S., & Bélec, L. (2021). Performances of the VitaPCR™ SARS-CoV-2 Assay during the second wave of the COVID-19 epidemic in France. Journal of medical virology, 93(7), 4351–4357.

  5. Fournier PE, Zandotti C, Ninove L, et al. Contribution of VitaPCR SARS-CoV-2 to the emergency diagnosis of COVID-19. J Clin Virol. 2020;133:104682.

CONTACT

We at Credo Diagnostics pioneer accessible diagnostic platforms to improve the lives of those we love. We believe providing the right information to the right people at the right time leads to better outcomes.